Cite
HARVARD Citation
Díaz‐Serrano, A. et al. (2018). Genomic Profiling of HER2‐Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2‐Positive Advanced Gastric Cancer Treated with Trastuzumab. Oncologist. pp. 1092-1102. [Online].